Kopran Limited · NSE:KOPRAN
Kopran — Q4 FY2022 Earnings Presentation
27 slides from Kopran's earnings presentation, May 31, 2022
Slide 1: Letter to stock exchanges on investor presentation
31st May, 2022 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol : KOPRAN Dear Sir
Slide 2: Kopran Limited Q4 FY 2022 Investor Presentation
KOPRAN LIMITED Q4 FY 2022 Investor Presentation
Slide 3: Safe Harbour Statement
Safe Harbour Statement This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o
Slide 4: Kopran Limited A Global Pharmaceutical Company
Kopran Limited A Global Pharmaceutical Company An integrated Presence across Pharmaceutical Company, pharmaceutical value chain committed to supplying 1 International Quality Formulations and Active APIs* Pharmaceutical Ingredients (APIs) globally State-of-the-art manufacturing facilities and 2 Inte
Slide 5: Business Overview API
Business Overview API API Vertical Dedicated and Versatile Facilities for: Product Segments Development, manufacturing and sale of diverse APIs and ◊ Atenolol ◊ Anti-hypertensive Advanced Intermediates ◊ Pregabalin ◊ Macrolides ◊ Cephalosporins - Non-Sterile & Sterile ◊ Neuromodulator One of the lea
Slide 6: Business Overview Formulations
Business Overview Formulations Formulations Vertical Product Segments Development and Penicillin-based Finished Oral Dosage Forms Non-Penicillin-based Finished Oral Dosage Forms manufacturing of oral solid dosages and dry powder ◊ Anti-infective ◊ Macrolides formulations for both Penicillin- ◊ Amoxy
Slide 7: FY 2021-22 Financial Highlights Summary
FY 2021-22 Financial Highlights Summary FY 2021-22 Performance (₹ Lakhs) The expansion and upgradation of two blocks at API facility at Mahad was YoY completed and resumed production at the end of April 2021. The expansion and Particulars FY 2021 FY 2022 (Change) upgradation of Sterile plant was com
Slide 8: Driving Sustainable Growth
Driving Sustainable Growth ◊ Focus on R&D to develop niche, high- ◊ Development of intermediates for APIs value/high-volume APIs and intermediates ◊ Reducing dependence on China to move ◊ Capacity expansion towards self sufficiency ◊ Compliance with Global Regulatory ◊ Optimising operational cost st
Slide 9: Research & Development: API
Driving Sustainable Growth Research & Development Developing knowledge and expertise through robust R&D API 1st Company to receive Drugs Controller General of India (DCGI) Our R&D team uses an innovative strategy to develop, 1 approval for launch of Biapenem in India and commercialise test, and manu
Slide 10: Research & Development: Product Pipeline
Driving Sustainable Growth Research & Development Widening our offerings through new products Product Pipeline Products to be commercialised Products under development, to in 2022-23 be commercialised after 2023 Products commercialised during the year ◊ Tebipenem ◊ Lacosamide ◊ Faropenem ◊ Buspirone
Slide 11: Research & Development: Formulations
Driving Sustainable Growth Research & Development Products filed and approvals received for our formulations Formulations Products filed during the year 138 dossiers filed in west Africa region 258 Total Dossiers 42 dossiers filed in south east Asia region Filed in FY 2021-22 72 dossiers filed in La
Slide 12: Capacity Expansion
Driving Sustainable Growth Capacity Expansion Progressing through consistent expansion of our facilities Panoli site: The work at Panoli site is progressing at full swing and we expect two blocks to be completed by July 2022 Commercial production is expected to commence in September 2022 Mahad site:
Slide 13: Regulatory Compliance
Driving Sustainable Growth Regulatory Compliance Offering best-in-class quality through strict compliance The Company maintains highest global regulatory Formulations Accreditations standards of manufacturing and quality at its all plants Approved by 15 countries including MHRA (UK), SAPHRA South Af
Slide 14: Operational Performance
OPERATIONAL PERFORMANCE
Slide 15: Operational Highlights: APIs Segment-wise Revenue Mix
Operational Highlights APIs Segment-wise Revenue Mix FY 2021-22 (₹ Lakhs) Q4 FY 2021-22 (₹ Lakhs) Advance Advance Intermediate 179.27 Intermediate Anti-Hypertensive 170.43 106.63 3,253.58 Anti-Hypertensive 1,035.09 4,796.49 1,544.94 Gastroenterology Anti-Thrombosis 2,887.89 1,143 Macrolides 124.33 M
Slide 16: Operational Highlights: APIs Market-wise Revenue Mix
Operational Highlights APIs Market-wise Revenue Mix FY 2021-22 (₹ Lakhs) Q4 FY 2021-22 (₹ Lakhs) 13,277.15 3,542.20 Local Sales Local Sales Export Sales Export Sales 14,597.70 4,410.59 Total ₹ 27,874.85 Lakhs Total ₹ 7,952.80 Lakhs 15
Slide 17: Operational Highlights: Formulations Region-wise Sales
Operational Highlights Formulations Region-wise Sales Break-up FY 2021-22 (₹ Lakhs) Q4 FY 2021-22 (₹ Lakhs) 1,757.55 871.69 Africa 626.32 7,684.49 Africa 2,075.23 274.1 Local Local 2,273.47 South Africa South Africa Southeast Asia 881.79 Southeast Asia UK UK 84.87 Latem Latem 221.45 7,951.44 2,027.6
Slide 18: Operational Highlights: Formulations Product-wise Revenue Mix
Operational Highlights Formulations Product-wise Revenue Mix FY 2021-22 (₹ Lakhs) Q4 FY 2021-22 (₹ Lakhs) 48.54 96.21 11,065.38 3,521.70 Non Pen Pen Plant Pen Plant Non pen Others Others 9,154.89 2,843.32 Total ₹ 20,316.48 Lakhs Total ₹ 6,413.57 Lakhs 17
Slide 19: Financial Performance
FINANCIAL PERFORMANCE
Slide 20: Financial Highlights: Quarterly Snapshot
Financial Highlights Quarterly Snapshot Sales/Other Income (₹ Lakhs) EBITDA * (₹ Lakhs) 2,713 2,697 2,402 14,455 13,597 14,392 13,008 1,934 7,816 928 Q-4 Q-1 Q-2 Q-3 Q-4 Q-4 Q-1 Q-2 Q-3 Q-4 2020-21 2021-22 2021-22 2021-22 2021-22 2020-21 2021-22 2021-22 2021-22 2021-22 *EBITDA excluding other income
Slide 21: Financial Highlights: Y-o-Y Snapshot
Financial Highlights Y-o-Y Snapshot Sales/Other Income (₹ Lakhs) EBITDA * (₹ Lakhs) 50,980 8,739 48,813 8,178 36,096 36,013 32,430 4,914 4,696 4,005 2017-18 2018-19 2019-20 2020-21 2021-22 2017-18 2018-19 2019-20 2020-21 2021-22 *EBITDA excluding other incomes Finance Costs (₹ Lakhs) Net Profit/(Los
Slide 22: Building Shareholder Value Year on Year
Financial Highlights Building Shareholder Value Year on Year… RoE (%) EBITDA & EBITDA Margin (₹ Lakhs, %) Total Debt/Equity (X) RoCE (%) 18.30 28.3 16.62 8,739 22.4 0.52 13.73 15.3 0.49 13.06 8,178 17.1 12.72 14.5 25.3 20.1 0.39 4,914 4,696 14.8 15.2 0.23 4,005 11.8 2017-18 2018-19 2019-20 2020-21 2
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights Particulars FY 2021-22 FY 2020-21 FY 2019-20 FY 2018-19 FY 2017-18 Revenue from 47,752 49,181.35 35,949.94 35,790.10 31,470.79 operations Equity share capital 4,821 4,325.16 4,324.89 4,324.89 4,324.89 Other equity 37,796 20,177.88 14,643.12 12,522.68 10,145.94 Netwo
Slide 24: Governance: Board of Directors
Governance Board of Directors Mr. Surendra Mr. Adarsh Mrs. Mamta Mr. Narayan Somani Rajendra Somani Biyani Atal Executive Vice Chairman Director Independent Director Independent Director Dr. Siddhan Dr. Sunita Mr. Susheel Mr. Varun Subramanian Banerji Somani Surendra Somani Independent Director Inde
Slide 25: Ownership Structure: Shareholding Pattern
Ownership Structure Kopran Limited Shareholding Pattern (%) 2.41 43.78 Kopran Kopran Research Kopran (H.K.) Promoters Lifesciences Laboratories Limited Limited Limited* Non-Institutions Financial Institutions Kopran (UK) Limited 53.82 24
Slide 26: Contact Us
Contact Us About Kopran Limited: Registered Office: Kopran Limited is an integrated Parijat House, For more information Pharmaceutical Company, 1076, Dr. E. Moses Road, about us, please visit committed to manufacturing and Worli, Mumbai − 400 018, www.kopran.com supplying International Quality Mahar
Slide 27: Thank You
THANK YOU